Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

Spotlight on Asia Pacific for Align

Align Technology Inc. (ALGN - Free Report) has announced the appointment of Julie Tay in the newly created position of vice president, Asia Paific. Tay will oversee business progression in the Asia Pacific region to attain a solid footing for the company. The officeholder’s primary responsibility is to focus on strategic development and operation management for all Align offerings and services in the region effective Mar 1, 2013.

Tay will acquire the responsibility for the company’s direct markets such as China and Japan, and 13 other indirect country markets across the Asia Pacific region. The Asia Pacific region remains one of the most highly sought-after avenues of growth for companies in the medical device space. Align’s latest announcement is expected to improve its execution in the geographical area. Moreover, Tay’s prior experience in the region is likely to yield positive results.

As disclosed earlier, Align has discontinued the distribution agreement with Invisalign Asia Pacific distributorship. Consequently, the company terminated indirect distribution network in four of the largest indirect country markets of Australia, New Zealand, Hong Kong and Singapore in the zone.

Nonetheless, this is expected to work in Align’s favor as it reverts back to direct sales in these countries on May 1, 2013. The other nine indirect country markets in Brunei, Indonesia, Macau, Malaysia, Philippines, South Korea, Taiwan, Thailand and Vietnam are expected to stick to the current distribution model.

Like other players in the industry, Align’s coherent focus on the Asia Pacific market is encouraging. Given the improving infrastructure, rising healthcare expenditure, demographic tailwinds and increasing income levels, strategic focus to expand its regional presence should result in a faster growth profile for the company.

The stock carries a Zacks Rank #3 (Hold). However, medical stocks such as Cyberonics , Given Imaging and Medical Action , each carrying a Zacks Rank #1 (Strong Buy) are expected to do well and warrant a look.

Resources

Client Support

Follow Us

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

Zacks Investment Research is an A+ Rated BBB Accredited Business.

Copyright 2016 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1988-2015 and were examined and attested by Baker Tilly Virchow Krause, LLP, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.